Solventum Corporation (SOLV)
(Delayed Data from NYSE)
$73.68 USD
+1.27 (1.75%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $73.71 +0.03 (0.04%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth F Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
SOLV 73.68 +1.27(1.75%)
Will SOLV be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for SOLV based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SOLV
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Will Solventum (SOLV) Beat Estimates Again in Its Next Earnings Report?
SOLV: What are Zacks experts saying now?
Zacks Private Portfolio Services
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
SOLV or MEDP: Which Is the Better Value Stock Right Now?
Take the Zacks Approach to Beat the Markets: Phibro Animal Health, Travelzoo, Ollie's Bargain Outlet in Focus
Other News for SOLV
Solventum commits to 100% renewable electricity by 2030
Solventum Reaches Analyst Target Price
Solventum appoints Ryan Egeland as CMO
Solventum appoints Ryan Egeland as Chief Medical Officer
Buy 4 October Dividend Aristocrats & Watch 10